1951483-29-6 Usage
Description
LY3214996 is a potent inhibitor of ERK1 and ERK2, with an IC50 value of 5 nM for both enzymes. It is a promising compound for the treatment of various types of cancer due to its ability to inhibit cell proliferation in tumor cells, particularly those expressing B-RAF, N-Ras, or K-Ras mutations.
Uses
Used in Oncology:
LY3214996 is used as an anticancer agent for the treatment of various types of cancer, including melanoma, colorectal, lung, and pancreatic cancer. It is particularly effective against tumors with B-RAF or N-Ras mutations and has shown efficacy in mouse xenograft models and patient-derived xenograft (PDX) mouse models.
Used in Cancer Research:
LY3214996 is used as a research tool for studying the role of ERK1 and ERK2 in cancer cell proliferation and tumor growth. Its potent inhibition of these enzymes makes it a valuable compound for investigating the underlying mechanisms of cancer development and progression.
Used in Drug Development:
LY3214996 serves as a starting point for the development of new cancer therapeutics targeting the ERK1/2 pathway. Its effectiveness in inhibiting tumor growth and its specificity for ERK1 and ERK2 make it a promising candidate for further optimization and development into a clinical drug.
Check Digit Verification of cas no
The CAS Registry Mumber 1951483-29-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,9,5,1,4,8 and 3 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1951483-29:
(9*1)+(8*9)+(7*5)+(6*1)+(5*4)+(4*8)+(3*3)+(2*2)+(1*9)=196
196 % 10 = 6
So 1951483-29-6 is a valid CAS Registry Number.
1951483-29-6Relevant articles and documents
COMBINATION OF ERK1/2 INHIBITOR COMPOUND WITH GEMCITABINE OR WITH GEMCITABINE AND NAB-PACLITAXEL FOR USE IN TREATMENT OF PANCREATIC CANCER
-
, (2018/09/25)
The present invention provides a combination of an ERK1/2 inhibitor compound, 6,6-dimethyl-2-{2-[(1-methyl-1H-pyrazol-5-yl)amino]pyrimidin-4-yl}-5-[2-(morpholin- 4-yl) ethyl]-5,6-dihydro-4H-thieno[2,3-c]pyrrol-4-one, or a pharmaceutically acceptable salt thereof, with gemcitabine, or a pharmaceutically acceptable salt thereof, preferably hydrochloride, or with gemcitabine, or a pharmaceutically acceptable salt thereof, preferably hydrochloride, and nab-paclitaxel, and to methods of using the combination to treat certain disorders, such as pancreatic cancer, including pancreatic ductal adenocarcinoma (PDAC).
